These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37801507)

  • 21. Correction of SCID-X1 using an enhancerless Vav promoter.
    Almarza E; Zhang F; Santilli G; Blundell MP; Howe SJ; Thornhill SI; Bueren JA; Thrasher AJ
    Hum Gene Ther; 2011 Mar; 22(3):263-70. PubMed ID: 20887212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage?
    Staal FJ; Pike-Overzet K; Ng YY; van Dongen JJ
    Leukemia; 2008 Oct; 22(10):1849-52. PubMed ID: 18769449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.
    Zhou S; Mody D; DeRavin SS; Hauer J; Lu T; Ma Z; Hacein-Bey Abina S; Gray JT; Greene MR; Cavazzana-Calvo M; Malech HL; Sorrentino BP
    Blood; 2010 Aug; 116(6):900-8. PubMed ID: 20457870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nuclease-free Adeno-Associated Virus-Mediated Il2rg Gene Editing in X-SCID Mice.
    Hiramoto T; Li LB; Funk SE; Hirata RK; Russell DW
    Mol Ther; 2018 May; 26(5):1255-1265. PubMed ID: 29606506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy.
    Pike-Overzet K; van der Burg M; Wagemaker G; van Dongen JJ; Staal FJ
    Mol Ther; 2007 Nov; 15(11):1910-6. PubMed ID: 17726455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promoter competition for gene therapy of SCID-X1.
    Baum C; Schambach A
    Hum Gene Ther; 2011 Mar; 22(3):255-6. PubMed ID: 21401346
    [No Abstract]   [Full Text] [Related]  

  • 27. Trial watch: Self-inactivating gene-therapy vector alleviates safety concerns.
    Cully M
    Nat Rev Drug Discov; 2014 Dec; 13(12):879. PubMed ID: 25394873
    [No Abstract]   [Full Text] [Related]  

  • 28. Faster T-cell development following gene therapy compared with haploidentical HSCT in the treatment of SCID-X1.
    Touzot F; Moshous D; Creidy R; Neven B; Frange P; Cros G; Caccavelli L; Blondeau J; Magnani A; Luby JM; Ternaux B; Picard C; Blanche S; Fischer A; Hacein-Bey-Abina S; Cavazzana M
    Blood; 2015 Jun; 125(23):3563-9. PubMed ID: 25869287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene therapy for PIDs: progress, pitfalls and prospects.
    Mukherjee S; Thrasher AJ
    Gene; 2013 Aug; 525(2):174-81. PubMed ID: 23566838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency.
    Chinen J; Davis J; De Ravin SS; Hay BN; Hsu AP; Linton GF; Naumann N; Nomicos EY; Silvin C; Ulrick J; Whiting-Theobald NL; Malech HL; Puck JM
    Blood; 2007 Jul; 110(1):67-73. PubMed ID: 17369490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo.
    Schwarzwaelder K; Howe SJ; Schmidt M; Brugman MH; Deichmann A; Glimm H; Schmidt S; Prinz C; Wissler M; King DJ; Zhang F; Parsley KL; Gilmour KC; Sinclair J; Bayford J; Peraj R; Pike-Overzet K; Staal FJ; de Ridder D; Kinnon C; Abel U; Wagemaker G; Gaspar HB; Thrasher AJ; von Kalle C
    J Clin Invest; 2007 Aug; 117(8):2241-9. PubMed ID: 17671654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials].
    Doi K; Takeuchi Y
    Uirusu; 2015; 65(1):27-36. PubMed ID: 26923955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous injection of a foamy virus vector to correct canine SCID-X1.
    Burtner CR; Beard BC; Kennedy DR; Wohlfahrt ME; Adair JE; Trobridge GD; Scharenberg AM; Torgerson TR; Rawlings DJ; Felsburg PJ; Kiem HP
    Blood; 2014 Jun; 123(23):3578-84. PubMed ID: 24642749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genotoxicity of retroviral hematopoietic stem cell gene therapy.
    Trobridge GD
    Expert Opin Biol Ther; 2011 May; 11(5):581-93. PubMed ID: 21375467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene therapy for SCID-X1: focus on clinical data.
    Baum C
    Mol Ther; 2011 Dec; 19(12):2103-4. PubMed ID: 22134740
    [No Abstract]   [Full Text] [Related]  

  • 36. T cell dynamics and response of the microbiota after gene therapy to treat X-linked severe combined immunodeficiency.
    Clarke EL; Connell AJ; Six E; Kadry NA; Abbas AA; Hwang Y; Everett JK; Hofstaedter CE; Marsh R; Armant M; Kelsen J; Notarangelo LD; Collman RG; Hacein-Bey-Abina S; Kohn DB; Cavazzana M; Fischer A; Williams DA; Pai SY; Bushman FD
    Genome Med; 2018 Sep; 10(1):70. PubMed ID: 30261899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid immune reconstitution of SCID-X1 canines after G-CSF/AMD3100 mobilization and in vivo gene therapy.
    Humbert O; Chan F; Rajawat YS; Torgerson TR; Burtner CR; Hubbard NW; Humphrys D; Norgaard ZK; O'Donnell P; Adair JE; Trobridge GD; Scharenberg AM; Felsburg PJ; Rawlings DJ; Kiem HP
    Blood Adv; 2018 May; 2(9):987-999. PubMed ID: 29720491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning.
    Huston MW; van Til NP; Visser TP; Arshad S; Brugman MH; Cattoglio C; Nowrouzi A; Li Y; Schambach A; Schmidt M; Baum C; von Kalle C; Mavilio F; Zhang F; Blundell MP; Thrasher AJ; Verstegen MM; Wagemaker G
    Mol Ther; 2011 Oct; 19(10):1867-77. PubMed ID: 21750532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Curing genetic disease with gene therapy.
    Williams DA
    Trans Am Clin Climatol Assoc; 2014; 125():122-8; discussion 128-9. PubMed ID: 25125725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells.
    Zhang F; Thornhill SI; Howe SJ; Ulaganathan M; Schambach A; Sinclair J; Kinnon C; Gaspar HB; Antoniou M; Thrasher AJ
    Blood; 2007 Sep; 110(5):1448-57. PubMed ID: 17456723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.